KORU Medical Systems, Inc. $(KRMD)$ has announced its financial results for the first quarter of 2025, reporting net revenues of $9.6 million, marking an 18% increase compared to the same period in the previous year. The core business, encompassing both domestic and international markets, achieved net revenues of $9.4 million, reflecting a 21% rise from the prior year period. The company's gross profit reached $6.0 million, a 19% increase over the prior year period, with a gross margin of 62.8%, showing a 50-basis point improvement. KORU Medical has also revised its full year 2025 revenue guidance upward to a range of $38.5 million to $39.5 million from the previous range of $38.0 million to $39.0 million. The company maintains its gross margin guidance of 61% to 63% and expects to achieve positive cash flow from operations for the full year. The ending cash balance for the quarter was $8.7 million, with a quarterly cash usage of $0.8 million. The company announced plans to submit two commercialized drugs for FDA 510(k) clearance with its Freedom Infusion System by the end of 2025. Despite facing a challenging macroeconomic environment, KORU Medical continues to experience positive business momentum, driven by new patient starts and increased market share both domestically and internationally.